There is an urgent need for vaccines to the 2019 coronavirus (COVID19;SARS-CoV-2) Vaccine development may not be straightforward, due to antibody-dependent enhancement (ADE) Antibodies against viral surface proteins can, in some cases, increase infection severity by ADE This phenomenon occurs in SARS-CoV-1, MERS, HIV, Zika and dengue virus infection and vaccination Lack of high-affinity anti-SARS-CoV-2 IgG in children may explain the decreased severity of infection in these groups Here, we discuss the evidence for ADE in the context of SARS-CoV-2 infection, and how to address this potential translational barrier to vaccine development, convalescent plasma, and targeted monoclonal antibody therapies
The Potential for Antibody-Dependent Enhancement of SARS-CoV-2 Infection: Translational Implications for Vaccine Development